Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 4-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)1H-imidazol-2-yl]-benzamide
- Correlated keywords
- inhibitors inhibits inhibition casein kinases 1 CK1 Ck1? TGF-? TGF? type-1 receptors ALK5 PKD1 p38? MAPK kinases phosphorylation FOXO1a RhoB p53 Smad3 D4476
- Product Overview:
D 4476 is a cell-permeant inhibitor of casein kinase 1 (CK1; IC50 = 200 nM from S. pombe,{17330} 300 nM for CK1?{17331}). It is a less effective inhibitor of PKD1 (IC50 = 9.1 ?M) and p38? MAPK (IC50 = 5.8 ?M), and only weakly affects the activities of a panel of kinases tested.{17331} D 4476 blocks CK1-mediated phosphorylation of FOXO1a,{17330} RhoB,{17333} and p53.{17334} As an inhibitor of ALK5, D 4476 prevents Smad3 activation and suppresses TGF-?1-induced gene expression without cytotoxicity in A498 cells.{16928}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.